News & Articles

From meeting challenges in solution prep to more 'flashy' analysis of the interaction between drugs, humans, and their contexts, we learn about the mounting importance of AI in drug discovery

Study done at the University of Cambridge suggests a way to predict prognosis and most effective treatment in cancer

Women with a rare type of ovarian cancer could benefit from a drug that quadruples the likelihood of response compared with standard therapies

Tell us which new products made the most difference to your lab work and you’ll have the chance to win one of four $500 Amazon gift cards

Meet one of the first cryo-EM groups set on delivering a resolution revolution

Read how GSK’s Method Innovation team is evaluating new technologies to drive efficiency in biopharma molecule development, in this exclusive interview

From patient-derived organoids to virus-specific T cells, explore the latest techniques and technologies advancing the field of precision medicine

Discover the latest technologies and techniques that are revolutionizing microbiome research

Dr. John Connolly, CSO of Tessa Therapeutics, reveals how a new approach to cell-based therapy in cancer could circumvent severe immunotherapy side effects and effectively target aggressive solid tumors

Get up to date on hot topics in the drug discovery community in our latest monthly compilation of content highlights

Integrated package of new and established services saves time and minimizes risks

Complementary product portfolios will support and accelerate expansion into the pharmaceutical industry

Side effects are similar to injectable glucagon, with the addition of nasal and eye-related symptoms

Join this expert webinar to find out how imaging and true 3D high-content analysis can benefit drug studies based on patient-derived organoids

New partnership to advance Nosopharm’s lead candidate to clinical stage

Phase 1 trial scheduled for early 2020 will be first CAR-T cell therapy clinical trial to employ SMARTvector technology

inStem’s Centre for Chemical Biology and Therapeutics to work with PhoreMost to progress selected targets

Eisai enters into collaborative research agreement with University of Dundee

Discover a range of new technologies and applications for biopharmaceutical development in this special editorial feature

This new range of kits is said to deliver high-quality ChIP-ready chromatin from as little as 5 Drosophila specimens

Novel cyclic IMS and new SYNAPT XS lead Waters’ portfolio of solutions that promise unlimited experimental opportunities and analytical flexibility